Polarean Imaging PLC Delivery of Xenon Polariser (7473C)
October 03 2018 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 7473C
Polarean Imaging PLC
03 October 2018
Polarean Imaging Plc
("Polarean" or the "Company")
Delivery of Xenon Polariser
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product for the magnetic resonance imaging (MRI) market, announces
the delivery of the latest model of Polarean's Xenon polariser to
The Department of Radiology at University of Missouri Health Care
("MUHC").
The Department of Radiology at MUHC is launching its research
programme in pulmonary imaging and will use Polarean's
hyperpolarised xenon technology as part of the programme.
Richard Hullihen, CEO of Polarean, said: "We are excited to
deliver the newest version of our polariser to MUHC. We are
grateful to Dr Altes, MUHC, and all the skilled researchers there,
for the opportunity to work together and continue our research into
the clinical applications of this emerging and much needed
technology."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861
6625
David Hignell / Gerry Beaney / Jamie Spotswood
(Corporate Finance)
Rob Rees (Corporate Broking)
MC Services (European IR) Tel: +49 (0)89 210
2280
Raimund Gabriel
The Life Sciences Division (Financial Adviser)
Navid Malik, Director Mob: 07957 224 730
Alia Minhas, CEO Mob: 07590 696 057
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
Helen Cresswell 741 001
+44 (0)7841 917 679
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate than current methods. The annual
burden of pulmonary disease in the US is estimated to be over
US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGMMGGKZRGRZM
(END) Dow Jones Newswires
October 03, 2018 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024